- Home
- NCMI vs PGEN Comparison
NCMI vs PGEN Comparison
Compare NCMI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- PGEN
- Stock Information
- Founded
- NCMI 2005
- PGEN 1998
- Country
- NCMI United States
- PGEN United States
- Employees
- NCMI N/A
- PGEN N/A
- Industry
- NCMI Advertising
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- PGEN Health Care
- Exchange
- NCMI Nasdaq
- PGEN Nasdaq
- Market Cap
- NCMI 434.8M
- PGEN 493.0M
- IPO Year
- NCMI 2007
- PGEN N/A
- Fundamental
- Price
- NCMI $4.70
- PGEN $3.84
- Analyst Decision
- NCMI Strong Buy
- PGEN Buy
- Analyst Count
- NCMI 4
- PGEN 5
- Target Price
- NCMI $7.00
- PGEN $7.50
- AVG Volume (30 Days)
- NCMI 446.0K
- PGEN 18.8M
- Earning Date
- NCMI 11-04-2025
- PGEN 08-12-2025
- Dividend Yield
- NCMI 2.57%
- PGEN N/A
- EPS Growth
- NCMI N/A
- PGEN N/A
- EPS
- NCMI N/A
- PGEN N/A
- Revenue
- NCMI $235,300,000.00
- PGEN $4,340,000.00
- Revenue This Year
- NCMI $5.40
- PGEN $253.63
- Revenue Next Year
- NCMI $14.48
- PGEN $699.64
- P/E Ratio
- NCMI N/A
- PGEN N/A
- Revenue Growth
- NCMI 13.34
- PGEN N/A
- 52 Week Low
- NCMI $4.12
- PGEN $0.65
- 52 Week High
- NCMI $7.60
- PGEN $5.23
- Technical
- Relative Strength Index (RSI)
- NCMI 55.31
- PGEN 55.85
- Support Level
- NCMI $4.28
- PGEN $3.89
- Resistance Level
- NCMI $4.74
- PGEN $5.23
- Average True Range (ATR)
- NCMI 0.17
- PGEN 0.34
- MACD
- NCMI 0.05
- PGEN -0.12
- Stochastic Oscillator
- NCMI 91.96
- PGEN 1.70
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.